The study is enrolling participants to see if the study drug REGN10597 is safe, tolerated, and effective in certain solid tumors that are in an advanced stage.

The study is enrolling participants to see if the disitamab vedotin works to treat bladder cancer when used alone or when it is used in combination with pembrolizumab.

The purpose of this study is to combine standard radiation therapy with drugs that stimulate the body's immune system against cancer cells (by targeting the protein PD-1), while adding drugs which also target the pathway that the tumor uses to evade the immune system (the CD73 and A2a/b pathways).The main goal of this study is to find out if study treatment with zimberelimab (an antibody which binds the protein PD-1) and stereotactic body radiation therapy (SBRT) alone or in combination with quemliclustat (a drug which blocks CD73), with or without etrumadenant (a drug which blocks the A2a/b) given before surgery is safe and if it can further increase the immune response against the tumor.

Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.

This study is being done to answer the following questions: 1) Can the study drug iberdomide be given after idecabtagene vicleucel (ide-cel (Abecma)) CAR-T in multiple myeloma safely and with acceptably few and mild side effects? 2) For how long does multiple myeloma stay under control (in remission) if patients receive the study drug iberdomide after they have received ide-cel (Abecma) CAR-T? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your multiple myeloma. The usual approach is defined as care most people get for multiple myeloma.

This study aims to understand how a person's race and where they live affect the quality of breast cancer care they receive. We invite Black and/or African American breast cancer patients and survivors from specific areas of North Carolina to participate in a virtual focus group. The purpose of this focus group is to get your feedback about maps and other tools our team has created to show how breast cancer care quality varies around the state and by race. We also want to hear your experiences seeking care in your area, and your ideas about possible reasons behind the patterns in your area.

Are you a cancer survivor? Have you survived breast or prostate cancer? If so, you may be able to participate in a study to see if AI chatbots give quality health advice to cancer survivors. We want to see if these responses can help providers and doctors respond well to patients' questions and needs.

Have you been diagnosed with Blood Cancer. If so, you may be able to take part in a research study looking at the safety of giving a new drug called AK117 to patients with Leukemia

This study will evaluate the safety, tolerability, and anti-tumor activity of amivantamab SC as monotherapy and in addition to pembrolizumab or paclitaxel in participants with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Are you at least 25 years old? Have you ever been referred for a colposcopy and had routine cervical cancer screening with HPV testing? If so, you may be able to take part in a study on newer ways to test for cervical cancer! We want to see if collecting vaginal samples on your own will give us the same results as when a doctor collects a cervical sample. Compensation provided.